Literature DB >> 17885061

Radiofrequency ablation in the management of liver metastases from breast cancer.

C T Sofocleous1, R G Nascimento, M Gonen, M Theodoulou, A M Covey, L A Brody, S M Solomon, R Thornton, Y Fong, G I Getrajdman, K T Brown.   

Abstract

OBJECTIVE: Systemic chemotherapy remains the standard treatment for patients with breast cancer hepatic metastases. Resection of metastases has survival advantages in a small percentage of selected patients. Radiofrequency ablation has been used in small numbers of selected patients. This small series was undertaken to review our experience with radiofrequency ablation in the management of patients with breast cancer hepatic metastases.
CONCLUSION: Radiofrequency ablation of breast cancer hepatic metastases is safe and may be used to control hepatic deposits in patients with stable or no extrahepatic disease.

Entities:  

Mesh:

Year:  2007        PMID: 17885061     DOI: 10.2214/AJR.07.2198

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  32 in total

1.  Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.

Authors:  Andrew C Gordon; William J Gradishar; Virginia G Kaklamani; Avesh J Thuluvath; Robert K Ryu; Kent T Sato; Vanessa L Gates; Riad Salem; Robert J Lewandowski
Journal:  J Vasc Interv Radiol       Date:  2014-08-22       Impact factor: 3.464

2.  A comparison of laparoscopic radiofrequency ablation versus systemic therapy alone in the treatment of breast cancer metastasis to the liver.

Authors:  Yunus Taşçi; Erol Aksoy; Halit Eren Taşkın; Shamil Aliyev; Halle Moore; Orhan Ağcaoğlu; Onur Birsen; Allan Siperstein; Eren Berber
Journal:  HPB (Oxford)       Date:  2013-10       Impact factor: 3.647

Review 3.  Locoregional Therapies for the Treatment of Hepatic Metastases from Breast and Gynecologic Cancers.

Authors:  Samdeep K Mouli; Ramona Gupta; Neil Sheth; Andrew C Gordon; Robert J Lewandowski
Journal:  Semin Intervent Radiol       Date:  2018-04-05       Impact factor: 1.513

Review 4.  Local treatment of oligometastatic disease: current role.

Authors:  Moritz T Winkelmann; Stephan Clasen; Philippe L Pereira; Rüdiger Hoffmann
Journal:  Br J Radiol       Date:  2019-06-06       Impact factor: 3.039

Review 5.  Improvement of survival and prospect of cure in patients with metastatic breast cancer.

Authors:  Yee Chung Cheng; Naoto T Ueno
Journal:  Breast Cancer       Date:  2011-05-13       Impact factor: 4.239

6.  Ultrasound-guided thermal radiofrequency ablation (RFA) as an adjunct to systemic chemotherapy for breast cancer liver metastases.

Authors:  G Carrafiello; F Fontana; E Cotta; M Petullà; L Brunese; M Mangini; C Fugazzola
Journal:  Radiol Med       Date:  2011-06-04       Impact factor: 3.469

Review 7.  Hepatic Metastasis from Breast Cancer.

Authors:  Ariel N Liberchuk; Amy R Deipolyi
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

Review 8.  Thermal ablation therapies in patients with breast cancer liver metastases: a review.

Authors:  Thomas J Vogl; Parviz Farshid; Nagy N N Naguib; Stephan Zangos
Journal:  Eur Radiol       Date:  2012-10-13       Impact factor: 5.315

9.  Radiofrequency thermal ablation (RFA) of hepatic metastases (METS) from breast cancer (BC): an adjunctive tool in the multimodal treatment of advanced disease.

Authors:  Andrea Veltri; Carlo Gazzera; Monica Barrera; Marco Busso; Federica Solitro; Claudia Filippini; Irene Garetto
Journal:  Radiol Med       Date:  2013-12-03       Impact factor: 3.469

10.  Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation--intermediate and long-term survival rates.

Authors:  Maria Franca Meloni; Anita Andreano; Paul F Laeseke; Tito Livraghi; Sandro Sironi; Fred T Lee
Journal:  Radiology       Date:  2009-08-25       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.